5 results found.

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using afatinib; placebo; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
afatinib; placebo; laboratory biomarker analysis

Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Ce Clinical Trial using Docetaxel; Cisplatin; 5-fluorouracil; Cetuximab Induction; Cetuximab Radioimmunotherapy; Boost irradiation

Arbeitsgemeinschaft medikamentoese Tumortherapie - Recruiting 18 years to 75 years.
- Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck.
Docetaxel; Cisplatin; 5-fluorouracil; Cetuximab Induction; Cetuximab Radioimmunotherapy; Boost irradiation

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
cisplatin; docetaxel; cetuximab; laboratory biomarker analysis; quality-of-life assessment; intensity-modulated radiation therapy

Oral Cancer, Oropharynx Cancer, or Hypopharynx Cancer Clinical Trial using IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Groupe Oncologie Radiotherapie Tete et Cou - Recruiting 18 years or older.
- Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma.
IMRT 75 Gy; Conventional radiotherapy 70 Gy; concomitant cisplatin

Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III S Clinical Trial using cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase Ib Trial of Concurrent Cetuximab (ERBITUXr) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOYr) in Locally Advanced Head and Neck Cancer.
cetuximab; intensity-modulated radiation therapy; ipilimumab; laboratory biomarker analysis